# Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo

> **NCT04618523** · PHASE4 · COMPLETED · sponsor: **Ministry of Public Health, Democratic Republic of the Congo** · enrollment: 1117 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Artesunate-amodiaquine
- **DRUG:** Artemether-lumefantrine

## Key facts

- **NCT ID:** NCT04618523
- **Lead sponsor:** Ministry of Public Health, Democratic Republic of the Congo
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 1117 (ACTUAL)
- **Last updated:** 2022-02-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618523, "Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04618523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*